BWAY
BrainsWay Ltd. [BWAY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BWAY Stock Summary
Top BWAY Correlated Resources
BWAY
Top 10 Correlated ETFs
BWAY
Top 10 Correlated Stocks
BWAY
In the News
BWAY Financial details
Company Rating
-
Market Cap
85.68M
Income
-4.2M
Revenue
31.79M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
134
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-13.66
Forward P/E
-
PEG
1.94
P/S
3.77
P/B
2.71
P/C
-
P/FCF
-30.95
Quick Ratio
5.76
Current Ratio
6.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.26
EPS next Y
-
EPS next Q
-
EPS this Y
-70.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-23.77%
Revenue last 5Y
6.59%
Revenue Q/Q
8.76%
EPS Q/Q
-155.63%
-
-
-
-
SMA20
10%
SMA50
22.22%
SMA100
10%
Inst Own
-
Inst Trans
-
ROA
-14%
ROE
-19%
ROC
-0.18%
Gross Margin
73%
Oper. Margin
-33%
Profit Margin
-28%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.38-7.615
52W High
+56.14%
52W Low
+993%
RSI
59
Rel Volume
0.32
Avg Volume
115.65K
Volume
36.47K
Perf Week
6.01%
Perf Month
21.18%
Perf Quarter
21.99%
Perf Half Y
8.86%
-
-
-
-
Beta
0.346
-
-
Volatility
0.4%, 0.87%
Prev Close
-4.29%
Price
10.93
Change
-4.71%
Company Profile
- Volume Average 115.65K
- Market Capitalization 85.68M
- Employee 134
- CEO Mr. Hadar Levy
- Headquarters Jerusalem,IL
- IPO Date 2019-04-17
-
Website
https://www.brainsway.com 
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
